Biblio

Author Title [ Type

] Year

Filters: Author is Kellner, Christian [Clear All Filters]

Journal Article

Oberg H-H, Kellner C, Gonnermann D, Peipp M, Peters C, Sebens S, Kabelitz D, Wesch D. γδ T cell activation by bispecific antibodies. Cell Immunol. 2015.

Kellner C, Lutz S, Oberg H-H, Wesch D, Otte A, Diemer KJ, Wilcken H, Bauerschlag D, Glüer C-C, Wichmann C, et al. Tumor cell lysis and synergistically enhanced antibody-dependent cell-mediated cytotoxicity by NKG2D engagement with a bispecific immunoligand targeting the HER2 antigen. Biol Chem. 2021.

Oberg H-H, Kellner C, Peipp M, Sebens S, Adam-Klages S, Gramatzki M, Kabelitz D, Wesch D. Monitoring Circulating γδ T Cells in Cancer Patients to Optimize γδ T Cell-Based Immunotherapy. Front Immunol. 2014;5:643.

Kellner C, Derer S, Klausz K, Rosskopf S, Wirt T, Rosner T, Otte A, Cappuzzello E, Peipp M. Fc Glyco- and Fc Protein-Engineering: Design of Antibody Variants with Improved ADCC and CDC Activity. Methods Mol Biol. 2018;1827:381-397.

Guenther A, Baumann P, Burger R, Kellner C, Klapper W, Schmidmaier R, Gramatzki M. Everolimus (RAD001) Activity in Relapsed and/or Refractory Multiple Myeloma: A Phase I Study. Haematologica. 2015.

Baumann N, Rosner T, Jansen JHMarco, Chan C, Eichholz KMarie, Klausz K, Winterberg D, Müller K, Humpe A, Burger R, et al. Enhancement of EGFR antibody tumor immunotherapy by glutaminyl cyclase inhibition to interfere with CD47/SIRPα interactions. Cancer Sci. 2021.

Schewe DM, Vogiatzi F, Münnich IA, Zeller T, Windisch R, Wichmann C, Müller K, Bhat H, Felix E, Mougiakakos D, et al. Enhanced potency of immunotherapy against B-cell precursor acute lymphoblastic leukemia by combination of an Fc-engineered CD19 antibody and CD47 blockade. Hemasphere. 2024;8(2):e48.

Derer S, Cossham M, Rosner T, Kellner C, Beurskens FJ, Schwanbeck R, Lohse S, Sina C, Peipp M, Valerius T. A Complement-Optimized EGFR Antibody Improves Cytotoxic Functions of Polymorphonuclear Cells against Tumor Cells. J Immunol. 2015.

Müller K, Vogiatzi F, Winterberg D, Rosner T, Lenk L, Bastian L, Gehlert CL, Autenrieb MPauline, Brüggemann M, Cario G, et al. Combining daratumumab with CD47 blockade prolongs survival in preclinical models of pediatric T-ALL. Blood. 2022.